Search Results
Your search for s matches 6967 pages
Showing 4101 - 4150Impact of Severe Fatigue on Treatment Outcome and Social Reintegration in Hodgkin Lymphoma
Severe cancer-related fatigue was associated with poorer clinical outcomes in patients receiving standard therapies for Hodgkin lymphoma and poorer social reintegration, according to an analysis of data from German Hodgkin Study Group trials reported in the Journal of Clinical Oncology by Behringer ...
HHS Finalizes MACRA Rule, ASCO Applauds Focus on High-Quality Patient-Centered Care
Today, the Department of Health & Human Services (HHS) finalized a landmark new payment system for Medicare clinicians that will continue the Administration’s progress in reforming how the health-care system pays for care. The Medicare Access and CHIP Reauthorization Act of ...
ESMO 2016: Fulvestrant Improves Progression-Free Survival in Advanced Breast Cancer
Fulvestrant (Faslodex) significantly increases progression-free survival in women with hormone receptor–positive advanced breast cancer, particularly those with less aggressive lower-volume disease, Ellis et al reported at the 2016 European Society for Medical Oncology (ESMO) Congress in ...
ESMO 2016: Longer Disease-Free Survival in Phase III Trial of Sunitinib as Adjuvant Treatment for Kidney Cancer
A phase III trial of sunitinib (Sutent) has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, reported Ravaud et al at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen (Abstract LBA11_PR)....
Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial (French Language Version) 
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses in French phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
Adding Health Navigation Assistance to Community Helpline Connected More People to Cancer Control Measures
A partnership that added health navigation services to 2-1-1 call centers helped a significant number of underserved Texans receive cancer control measures such as Papanicolaou (Pap) tests and smoking cessation help, according to a study (PR12, C49) presented at the 9th Association for Cancer...
African American Cancer Survivors More Likely to Experience Lasting Debt Related to Cancer and Its Treatment
African American cancer survivors are more likely than whites to experience lasting debt or forgo necessary medical care as they struggle with the financial burden of cancer, while whites are somewhat more likely to use existing assets to pay for their cancer care, according to a study (C13)...
Affordable Care Act Increased Access to Cancer Care and Clinical Trial Participation Among Hispanics
Implementation of the Affordable Care Act (ACA) in California may have led to a significant increase in the number of Hispanic breast cancer patients at a National Cancer Institute (NCI)-designated cancer center and an increase in the number of Hispanic women who consented to participate in a...
HHS Takes Steps to Provide More Information on Clinical Trials to the Public
To make information about clinical trials widely available to the public, the U.S. Department of Health and Human Services (HHS) issued a final rule on September 19 that specifies requirements for registering certain clinical trials and submitting summary results information to ClinicalTrials.gov....
Expect Questions About the FDA Discouraging Use of Ovarian Cancer Screening Tests
The release of a U.S. Food and Drug Administration (FDA) Safety Communication “alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests”1 and recommending against using these tests comes not as a result of startling new studies, but from an...
ASCO Supports Recent Tobacco Legislation
On August 8, the U.S. Food and Drug Administration’s (FDA) rule giving the agency the authority to regulate e-cigarettes, cigars, hookahs, and pipe tobacco took effect. In May, ASCO applauded the FDA for exercising its congressionally mandated authority to regulate e-cigarettes as a crucial step in ...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)
Ever since the immune checkpoint agents arrived, the pace of clinical investigation in oncology has continued to accelerate with an ever-increasing number of trials of single-agent and combination therapies with novel designs that are transforming our drug-development process. However, even in...
Why Curing Cancer Will Take Decades
This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...
FDA Grants Breakthrough Therapy Designation for First-Line Treatment of ALK-Positive NSCLC
On October 4, 2016, the U.S. Food and Drug Administration (FDA) granted alectinib (Alecesna), an anaplastic lymphoma kinase (ALK) inhibitor, a second Breakthrough Therapy designation. This latest designation was granted for the treatment of adult patients with advanced ALK-positive non–small...
Bridging the Gap in Oncology Care
The third annual Palliative Care in Oncology Symposium, held on September 9–10, 2016, in San Francisco, California, brought together more than 650 attendees from multiple countries, including the United States, Canada, the United Kingdom, France, Italy, and China. It featured over 250 study...
Does Adding Adjuvant Bevacizumab to Capecitabine Benefit Patients With Colorectal Cancer?
Kerr et al found that adding adjuvant bevacizumab (Avastin) to capecitabine did not improve disease-free survival in unselected patients with stage III or high-risk stage II colorectal cancer. The results of the phase III QUASAR 2 trial were reported in The Lancet Oncology. Study Details In the...
Prehabilitation and Rehabilitation May Improve Work-Related Outcomes in Cancer Survivors
In August 2016, the Healthcare Delivery Research Program of the Division of Cancer Control and Population Sciences at the National Cancer Institute convened a group of experts in a variety of fields to identify a research agenda for optimizing employment outcomes among cancer survivors. A core...
Phase II Trial Shows Benefit of Ibrutinib in Relapsed/Refractory CLL With 17p Deletion
O’Brien et al found further evidence of the benefit of ibrutinib (Imbruvica) in relapsed/refractory chronic lymphocytic leukemia (CLL) with the 17p deletion, according to an extended analysis of the phase II RESONATE-17 trial reported in The Lancet Oncology. Ibrutinib currently is approved...
ASTRO 2016: Stereotactic Radiosurgery Decreases Rate of Postoperative Local Recurrence for Brain Metastases
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence, but shows no positive difference in terms of overall survival or distant brain metastases rates when compared to observation alone following surgical...
ASTRO 2016: SBRT Offers Patients With Prostate Cancer High Disease Control and Low Toxicity in Fewer Treatments
High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the...
ASTRO 2016: Reduced Radiation Boost Volume Recommended for Average-Risk Pediatric Medulloblastoma, but Craniospinal Axis Dose Remains Unchanged
In the largest trial conducted for average-risk medulloblastoma, survival rates following reduced radiation therapy boost volumes were comparable to standard treatment volumes for the primary tumor site, but lower doses of craniospinal axis irradiation were associated with higher event rates and...
ASTRO 2016: Postoperative Stereotactic Radiosurgery: New Standard of Care for Patients With Resected Brain Metastases?
For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline, and better quality of life, compared to whole-brain radiotherapy (WBRT), according to research presented at the 58th Annual ...
ASTRO 2016: Three Novel Intrinsic Subtypes of Prostate Cancer Identified
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research...
ASTRO 2016: Advances in Radiation Therapy Have Improved Survival Rates for Patients With Early-Stage Lung Cancer
A new analysis of records in the Veterans Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non–small cell lung cancer (NSCLC) in recent years, according to research presented...
ASTRO 2016: Intermediate-Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...
ASCO/ASTRO/SSO Develop Focused Guideline Update on Postmastectomy Radiotherapy
As reported by Recht et al in the Journal of Clinical Oncology, a joint ASCO, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) panel has developed a focused guideline update of the ASCO guideline on postmastectomy radiotherapy. A recent Cancer Care Ontario...
ASTRO 2016: Hypofractionated Radiation Therapy Can Reduce Treatment Time With Comparable Quality of Life for Patients With Prostate Cancer
For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy offers comparable health-related quality of life outcomes in one-third less treatment time than conventional radiation therapy, according to research presented by Watkins Bruner et al at the 58th...
ASTRO 2016: Widespread Adoption of SBRT Has Improved Survival Rates for Elderly Patients With Early-Stage Lung Cancer
Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non–small cell lung cancer (NSCLC) rose from roughly 40% to 60% over the past decade, concurrent with the increasing adoption of SBRT, according to research presented by Dalwadi et al...
Ratio of Certain Immune Cells in the Blood to Tumor Burden Correlated With Outcome for Melanoma Patients Treated With Pembrolizumab
Although some patients with melanoma experience durable responses to treatment with the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda), the majority of patients do not experience a durable clinical benefit from anti–PD-1 monotherapy, according to a study by ...
Addition of CHK1 Inhibitor Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Combining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemoradiotherapy for head and neck cancers and stop cells becoming resistant to treatment. Researchers at The Institute of Cancer Research, London (ICR), and The Royal Marsden...
Blood Biomarkers in Abiraterone- or Enzalutamide-Resistant Prostate Cancer Tumor Cells
While searching for a noninvasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. In a study published by Gupta et al in Clinical Cancer Research, a team...
10-Year Risk of Invasive Breast Cancer After Diagnosis of Atypical Ductal Hyperplasia by Needle Biopsy
The cumulative estimated risk of invasive breast cancer at 10 years after diagnosis of atypical ductal hyperplasia by core-needle biopsy was approximately 5%, according to a study reported by Menes et al in JAMA Oncology. The 10-year risk was 6.7% with atypical ductal hyperplasia diagnosed by...
Combining Ipilimumab With Radiotherapy in Advanced Melanoma
The immunotherapy ipilimumab (Yervoy) has revolutionized the treatment of malignant melanoma and resulted in durable responses in 20% to 25% of patients with the cancer. Sebastian Theurich, MD, of the Center for Integrated Oncology at the University Hospital of Cologne in Germany, and colleagues...
Recognizing the Unique Experiences of Cancer Among Adolescent and Young Adult Survivors
Studies show that adolescent and young adult cancer survivors experience distinct challenges and quality-of-life issues from those experienced by either younger or older adult cancer survivors and that those challenges and issues can persist long after the cancer diagnosis and the end of...
The Role of Music Therapy in Cancer Care
Music therapy, an established adjuvant to standard cancer care, is offered in a growing number of cancer centers throughout the United States and internationally. Defined by the American Music Therapy Association (AMTA) as “the evidence-based use of music interventions to accomplish individual...
High-Calcium, Low-Lactose Diet May Reduce Risk of Ovarian Cancer in African American Women
Research from Rutgers Cancer Institute of New Jersey and and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African American women. The work, published by Qin et al in the British Journal of Cancer, also found sun ...
Neoadjuvant Veliparib/Carboplatin and Neratinib ‘Graduate’ From Adaptive Randomization I-SPY 2 Trial in Early Breast Cancer
As reported by Hope S. Rugo, MD, and John W. Park, MD, both of the University of California, San Francisco, and colleagues in The New England Journal of Medicine, the multiarm adaptive randomization phase II I-SPY 2 trial has shown that the addition of veliparib/carboplatin and the addition of...
Continuation of Docetaxel May Improve Survival in Metastatic Castration-Resistant Prostate Cancer
The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid) or docetaxel/prednisone, in the phase III Mainsail trial. de Morrée et al reported this ...
Everolimus in Advanced HER2-Positive Breast Cancer With PIK3CA Mutation, PTEN Loss, or Hyperactive PI3K Pathway
In an analysis of the phase III BOLERO-1 and -3 trials reported in the Journal of Clinical Oncology, Fabrice André, MD, of Institut Gustav-Roussy, Paris, France, and colleagues found that the addition of everolimus (Afinitor) to trastuzumab (Herceptin) and chemotherapy was associated with a...
ASH Presents Charles Mullighan, MBBS (Hons), MD, With the 2016 William Dameshek Prize
The American Society of Hematology (ASH) will present the 2016 William Dameshek Prize to Charles Mullighan, MBBS (Hons), MD, of St. Jude Children’s Research Hospital, for his leadership in defining the landscape of genetic alterations of acute lymphocytic leukemia (ALL), which has provided...
Routine PET Surveillance Discouraged in Large Cell Lymphoma
There is no role for routine imaging as a means of following patients with large cell lymphoma, according to Bruce D. Cheson, MD, Deputy Chief of Hematology-Oncology and Professor of Medicine at Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC. “Routine...
Enhanced Survival With Implantable Scaffolds That Capture Metastatic Breast Cancer Cells in Vivo
A small device implanted under the skin may improve breast cancer survival by catching cancer cells, slowing the development of metastatic tumors in other organs, and allowing time to intervene with surgery or other therapies. These findings, reported by Rao et al in Cancer Research, suggest a path ...
Testosterone Therapy May Be Cardioprotective in Patients Undergoing Chemotherapy
The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Among the patients studied,...
Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC
For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...
Early Studies Examine Response of CML-Initiating Cells to Ezh2 Inhibition
Although targeted drugs like imatinib (Gleevec) have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. New research conducted by scientists at Dana-Farber Cancer Institute...
Decisional Regret After Initial Treatment Decisions Among Parents of Children With Cancer
Racial/ethnic minority parents were more likely to express regret about initial cancer treatment decisions for their children, according to a study reported in the Journal of Clinical Oncology. Mack et al found that factors associated with less decisional regret included receiving high-quality...
First-Line Nivolumab Alone and Combined With Platinum-Based Chemotherapy in Advanced NSCLC
The phase I CheckMate 012 study examined the effects of nivolumab (Opdivo) monotherapy and nivolumab combined with platinum-based doublets as first-line treatments in patients with advanced non–small cell lung cancer (NSCLC). Encouraging efficacy and safety findings were reported in the Journal...
Adolescent Girls With Leukemia May Not Be Screened for Pregnancy Before Beginning Chemotherapy
A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects. These findings were published by Rao et al in Cancer. Although many chemotherapy drugs can cause birth defects, there are no...
